These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

95 related articles for article (PubMed ID: 1838979)

  • 1. ESGAB breakpoint determination: clarithromycin.
    Phillips I; Acar J; Baquero F; Bergan T; Forsgren A; Wiedemann B
    Eur J Clin Microbiol Infect Dis; 1991 Nov; 10(11):993-4. PubMed ID: 1838979
    [No Abstract]   [Full Text] [Related]  

  • 2. In vitro activity of clarithromycin and its 14-hydroxy-metabolite against 203 strains of Haemophilus influenzae.
    Bergeron MG; Bernier M; L'Ecuyer J
    Infection; 1992; 20(3):164-7. PubMed ID: 1386590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative in vitro activity of azithromycin, clarithromycin, erythromycin and lomefloxacin against Mycoplasma pneumoniae, Mycoplasma hominis and Ureaplasma urealyticum.
    Renaudin H; Bébéar C
    Eur J Clin Microbiol Infect Dis; 1990 Nov; 9(11):838-41. PubMed ID: 1964899
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activity of clarithromycin and its principal human metabolite against Haemophilus influenzae.
    Jorgensen JH; Maher LA; Howell AW
    Antimicrob Agents Chemother; 1991 Jul; 35(7):1524-6. PubMed ID: 1834012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility of Haemophilus influenzae to clarithromycin alone and in combination with its 14-hydroxy metabolite.
    Barry AL; Fuchs PC; Pfaller MA
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1080-1. PubMed ID: 1839381
    [No Abstract]   [Full Text] [Related]  

  • 6. In-vitro cidal activity of clarithromycin and its 14-hydroxy metabolite (A-62671) against Haemophilus influenzae.
    Powell M; Chen HY; Weinhardt B; Williams JD
    J Antimicrob Chemother; 1991 May; 27(5):694-6. PubMed ID: 1832146
    [No Abstract]   [Full Text] [Related]  

  • 7. Individual and combined activities of clarithromycin and its 14-hydroxy metabolite in a murine model of Haemophilus influenzae infection.
    Vallée E; Azoulay-Dupuis E; Swanson R; Bergogne-Bérézin E; Pocidalo JJ
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():31-41. PubMed ID: 1827100
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bactericidal activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae and streptococcal pathogens.
    Gu JW; Scully BE; Neu HC
    J Clin Pharmacol; 1991 Dec; 31(12):1146-50. PubMed ID: 1837032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clarithromycin and azithromycin.
    Med Lett Drugs Ther; 1992 May; 34(870):45-7. PubMed ID: 1315414
    [No Abstract]   [Full Text] [Related]  

  • 10. Azithromycin and clarithromycin.
    Hammerschlag MR
    Pediatr Ann; 1993 Mar; 22(3):160, 162-4, 166. PubMed ID: 8385308
    [No Abstract]   [Full Text] [Related]  

  • 11. The activity of clarithromycin and its 14-hydroxy metabolite against Haemophilus influenzae, determined by in-vitro and serum bactericidal tests.
    Dabernat H; Delmas C; Seguy M; Fourtillan JB; Girault J; Lareng MB
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():19-30. PubMed ID: 1827099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In-vitro activity of clarithromycin combined with its 14-hydroxy metabolite A-62671 against Haemophilus influenzae.
    Olsson-Liljequist B; Hoffman BM
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():11-7. PubMed ID: 1827097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-hydroxy-clarithromycin, its major metabolite in humans.
    Hardy DJ; Swanson RN; Rode RA; Marsh K; Shipkowitz NL; Clement JJ
    Antimicrob Agents Chemother; 1990 Jul; 34(7):1407-13. PubMed ID: 2143642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro and disc susceptibility testing of clarithromycin and its 14-hydroxy metabolite.
    Logan MN; Ashby JP; Andrews JM; Wise R
    J Antimicrob Chemother; 1991 Feb; 27(2):161-70. PubMed ID: 1829073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of A-56268 compared with that of erythromycin and other oral agents against aerobic and anaerobic bacteria.
    Chin NX; Neu NM; Labthavikul P; Saha G; Neu HC
    Antimicrob Agents Chemother; 1987 Mar; 31(3):463-6. PubMed ID: 2953303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activity of tosufloxacin (A-60969) and clarithromycin (A-56268, TE-031) against resistant Haemophilus influenzae, Streptococcus pneumoniae and Branhamella catarrhalis isolates.
    Bryan JP; Waters C; Sheffield J; Wagner KF
    Eur J Clin Microbiol Infect Dis; 1990 May; 9(5):361-5. PubMed ID: 2142647
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clarithromycin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic potential.
    Peters DH; Clissold SP
    Drugs; 1992 Jul; 44(1):117-64. PubMed ID: 1379907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of clarithromycin against Mycoplasma pneumoniae.
    Cassell GH; Drnec J; Waites KB; Pate MS; Duffy LB; Watson HL; McIntosh JC
    J Antimicrob Chemother; 1991 Feb; 27 Suppl A():47-59. PubMed ID: 1827102
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparative study on the macrolides erythromycin and clarithromycin: antibacterial activity and influence on immune responses.
    Roszkowski K; Beuth J; Ko HL; Peters G; Pulverer G
    Zentralbl Bakteriol; 1990 Sep; 273(4):518-30. PubMed ID: 2147373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postantibiotic effects of ABT-773 and amoxicillin-clavulanate against Streptococcus pneumoniae and Haemophilus influenzae.
    Neuhauser MM; Prause JL; Danziger LH; Pendland SL
    Antimicrob Agents Chemother; 2001 Dec; 45(12):3613-5. PubMed ID: 11709352
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.